Pharmacokinetics and tolerability of <scp>SRT</scp>2104, a first‐in‐class small molecule activator of <scp>SIRT</scp>1, after single and repeated oral administration in man

Abstract

In the absence of an optimized formulation of SRT2104, the food effect can be used to maximize exposure in future clinical studies. Combined with the good tolerability of all doses demonstrated in these studies, the favourable selectivity profile of SRT2104 allows for the use of this SIRT1 modulator for target validation in the clinic.